The board of directors appointed Peter Radovich as an independent Class I director effective October 20, 2026. He will serve until the 2028 Annual Meeting of Stockholders. The board set its size at eight directors. Mr. Radovich received an initial award of a non-qualified stock option to purchase 18,200 shares and cash compensation per the Non-Employee Director Compensation Policy. MBX Biosciences develops therapies for infectious diseases.
